Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy
2017 · Redox Biology · 169 citations
https://doi.org/10.1016/j.redox.2017.10.010
I
Isabel Lastres‐Becker
Biomedical Research Networking Center on Neurodegenerative Diseases(ES)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
74
Papers
5.4K
Citations
38
h-index
57
i10-index
Isabel Lastres‐Becker is an academic researcher from Biomedical Research Networking Center on Neurodegenerative Diseases. The author has contributed to research in topics: Cannabis and Cannabinoid Research & Genomics, phytochemicals, and oxidative stress & Neuroscience and Neuropharmacology Research. The author has an h-index of 38, co-authored 63 publications.
ORCID: 0000-0002-4968-2175Papers by this author
worksBiomarkers of NRF2 signalling: Current status and future challenges
2024 · Redox Biology · 102 citations
https://doi.org/10.1016/j.redox.2024.103134
Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate
2015 · Neurogenetics · 70 citations
https://doi.org/10.1007/s10048-015-0441-5
CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies
2019 · Redox Biology · 65 citations
https://doi.org/10.1016/j.redox.2019.101118
Ataxin-2 Modulates the Levels of Grb2 and Src but Not Ras Signaling
2013 · Journal of Molecular Neuroscience · 57 citations
https://doi.org/10.1007/s12031-012-9949-4
NRF2-dependent gene expression promotes ciliogenesis and Hedgehog signaling
2019 · Scientific Reports · 24 citations
https://doi.org/10.1038/s41598-019-50356-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat